Search Results

Tranquis Therapeutics, Inc. today announced it will present preclinical data on the anti-aging effects of TQS-168, a small molecule modulator of PGC-1 a, at ARDD 2022, the 9th Aging Research and Drug Discovery meeting, taking place August 29 to September 2, 2022 at the University of Copenhagen, Denmark.

Tranquis Therapeutics announced that members of its management team will participate in the following investor conferences in March 2022:

Tranquis plans to start a Phase 2 trial in people living with ALS by the end of 2022.

Tranquis Therapeutics today announced the initiation of dosing in a Phase 1 clinical study of TQS-168 in healthy volunteers.

Tranquis Therapeutics, Inc., a clinical stage immuno-neurology company developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases, today announced the completion of its Phase 1 clinical trial of TQS-168, a small molecule modulator of PGC-1a in development for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Tranquis Therapeutics announced its CEO, Sanjak Kakkar, M.D. will give a corporate presentation at the Biotech Showcase, being held January 10-19, 2022.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Tranquis Therapeutics, today announced it presented positive preclinical data on its lead program TQS-168 at the Neuroscience 2021 meeting, which is the annual meeting of the Society for Neuroscience (SfN).

Tranquis Therapeutics today announced it has strengthened its management team with the addition of Faisal Shawwa, MBA, as Senior Vice President of Finance and Administration and Janet Hurt, MPH, as Senior Vice President of Clinical Evidence Generation.